Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pradofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 5/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 5/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pradofloxacin SCHEMBL2201509 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL150884 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7678035 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL30595280 | 0.99 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7962325 | 0.99 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7962442 | 0.96 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7976296 | 0.95 | KDM4E (0.69) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL9181426 | 0.92 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL7962516 | 0.90 | KDM4E (0.67) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7975579 | 0.90 | KDM4E (0.63) | ALDH1A1KDM4EHPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882049-B1 | POSSIBLY SUBSTITUTED 8-CYANO-1-CYCLOPROPYL-7-(2,8-DIAZABICYCLO- 4.3.0]-NONAN-8-YL)-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLIN CARBOXYLIC ACIDS AND THEIR DERIVATIVES | BAYER AG (DE) | 2002-11-20 | — | — | EP | claimed |
| US-6323213-B1 | ANTIBIOTICS, BACTERICIDES FOR VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | claimed |
| CN-117849219-A | Method for detecting content of pramipexole | 上海汉维生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117466886-A | New prafloxacin hydrate crystal form and preparation method and application thereof | 瑞普（天津）生物药业有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-3579820-B1 | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN | BAYER ANIMAL HEALTH GMBH (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-2170272-B1 | IMPROVED TASTE-MASKING EXTRUDATES | BAYER IP GMBH (DE) | 2017-03-29 | — | — | EP | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| WO-2009147144-A2 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL B.V. (NL) | 2009-12-10 | — | — | WO | disclosed |
| US-6323213-B1 | ANTIBIOTICS, BACTERICIDES FOR VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| US-6323213-B1 | ANTIBIOTICS, BACTERICIDES FOR VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| US-6323213-B1 | ANTIBIOTICS, BACTERICIDES FOR VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| CN-1073112-C | Optionally substituted 8-cyano-1-cyclopropyl-7- (2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and derivatives thereof | BAYER AG (DE) | 2001-10-17 | — | — | CN | disclosed |
| CN-1073112-C | Optionally substituted 8-cyano-1-cyclopropyl-7- (2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and derivatives thereof | BAYER AG (DE) | 2001-10-17 | — | — | CN | disclosed |
| US-6278013-B1 | AS CHEMICAL INTERMEDIATES FOR PREPARING QUINOLINECARBOXYLIC ACID DERIVATIVE ANTIBIOTICS USED IN VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-21 | — | — | US | disclosed |
| US-6278013-B1 | AS CHEMICAL INTERMEDIATES FOR PREPARING QUINOLINECARBOXYLIC ACID DERIVATIVE ANTIBIOTICS USED IN VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-21 | — | — | US | disclosed |
| CN-1211984-A | Optionally substituted 8-cyano-1-cyclopropyl-7- (2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and derivatives thereof | BAYER AG (DE) | 1999-03-24 | — | — | CN | disclosed |
| CN-1211984-A | Optionally substituted 8-cyano-1-cyclopropyl-7- (2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and derivatives thereof | BAYER AG (DE) | 1999-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | ALDH1A1 1287/4885KDM4E 3174/4885HPGD 324/4885 |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | ALDH1A1 1287/4885KDM4E 3174/4885HPGD 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.